Timothy Schmidt

11PUBLICATIONS
32CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman

|Jan 25, 2024
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.

Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal

|Dec 15, 2023
Update on the current and future use of CAR-T to treat multiple myeloma.

Zhubin Gahvari, Matthew Brunner, Timothy Schmidt

|Aug 21, 2023
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation.

Rebecca W Silbermann, Timothy Martin Schmidt, Susan Bal

|Dec 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.

Luciano J Costa, Saurabh Chhabra, Eva Medvedova

|May 13, 2021
Progress in the Management of Smoldering Multiple Myeloma.

Timothy M Schmidt, Natalie S Callander

Pageof 2

Frequent Collaborators

4 joint publications

Natalie S Callander

3 joint publications

Luciano J Costa

2 joint publications

Parameswaran Hari

2 joint publications

Jonathan L Kaufman